Experimental Chemo Combo for Colon Cancer Disappoints

TUESDAY, Apr 3 (HealthDay News) — Adding a drug cetuximab
(brand name Erbitux) to customary chemotherapy after medicine for theatre 3colon cancer did not urge disease-free presence in patients, a new
study concludes.

Patients with theatre 3 colon cancer who bear medicine have a 50
percent possibility of cure, and clinical trials have found that chemotherapy
with a drugs leucovorin, fluorouracil and oxaliplatin (a fast known
as FOLFOX) after medicine can cut a contingency for colon cancer’s return.

Staging refers to a astringency of cancer. A theatre 3 cancer has spread
nearby, while a stage 4 cancer has widespread to another organ.

This investigate of roughly 2,700 patients investigated a further of
cetuximab to a FOLFOX fast and found that it supposing no extra
benefit.

Three-year disease-free presence for patients who perceived a FOLFOX
regimen alone ranged from 67 percent to 75 percent, c...